Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 7/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 3/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26161150 | 0.99 | PDK2 (0.39) | PDK2CYP11B1CYP11B2PIM1PIM3 | |
| SCHEMBL26161067 | 0.94 | PDK2 (0.45) | PDK2CYP11B1CYP11B2PIM1PIM3 | |
| SCHEMBL26161249 | 0.93 | PDK2 (0.44) | PDK2CYP11B1CYP11B2PIM1PIM3 | |
| SCHEMBL15977609 | 0.91 | PDK2 (0.43) | PDK2CYP11B1CYP11B2PIM1PIM3 | |
| SCHEMBL15977831 | 0.90 | PDK2 (0.43) | PDK2CYP11B1CYP11B2PIM1PIM3 | |
| SCHEMBL15977588 | 0.88 | PDK2 (0.44) | PDK2CYP11B1CYP11B2PIM1PIM3 | |
| SCHEMBL26161307 | 0.88 | PDK2 (0.36) | PDK2FEN1ALOX5AP | |
| SCHEMBL15977516 | 0.87 | PDK2 (0.45) | PDK2CYP11B1CYP11B2PIM1PIM3 | |
| SCHEMBL20176480 | 0.86 | PDK2 (0.39) | PDK2FEN1ALOX5AP | |
| SCHEMBL20176471 | 0.86 | PDK2 (0.37) | PDK2CYP11B1CYP11B2FEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667622-B2 | Organic light emitting compound and organic electroluminescence device using same | SOLUS ADVANCED MATERIALS CO., LTD. (KR) | 2023-06-06 | — | — | US | disclosed |
| US-11667622-B2 | Organic light emitting compound and organic electroluminescence device using same | SOLUS ADVANCED MATERIALS CO., LTD. (KR) | 2023-06-06 | — | — | US | disclosed |
| WO-2018093231-A1 | ORGANIC LIGHT EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING SAME | 주식회사 두산 | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667622-B2 | Organic light emitting compound and organic electroluminescence device using same | OR10J3, ICMT, SLCO4C1 | PDK2 1916/4885CYP11B1 836/4885CYP11B2 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.